Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review.
Adam M. Kaye: 0000-0002-7224-3322
Health Psychology Research
An intranasal formulation of midazolam, Nayzilam, has been FDA-approved to treat intermittent, stereotypic episodes of frequent seizure activity. Nayzilam is easy to administer and can quickly treat seizures that occur outside of the hospital. The intra-nasal route of administration allows non-medical personal to administer the drug which makes it more accessible and user-friendly in the event of a seizure. Many studies have indicated quick cessation of seizures with Nayzilam compared to rectal diazepam, which has been the standard of care treatment. Nayzilam has been proven to be safe and effective for acute seizures in children, deeming it a revolutionary alternative in times where intravenous administration is not possible.
Cornett, E. M.,
Nemomsa, M. A.,
Busby, M. A.,
Kaye, J. S.,
Kaye, A. J.,
Ramírez, G. F.,
Kaye, A. M.,
Kaye, A. D.,
Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review..
Health Psychology Research, 10(5), 38536–38536.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Biochemistry, Biophysics, and Structural Biology Commons, Chemicals and Drugs Commons, Pharmacy and Pharmaceutical Sciences Commons